CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M

Reuters

2025/08/08

CytoSorbents <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M

CytoSorbents Corporation $(CTSO)$ has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557595180"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557595180\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557595180?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557595180","market":"fut","top_or_hot":-1,"title":"CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoSorbents <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoSorbents Corporation <a href=\"https://laohu8.com/S/CTSO\">$(CTSO)$</a> has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoSorbents <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoSorbents Corporation <a href=\"https://laohu8.com/S/CTSO\">$(CTSO)$</a> has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTSO","symbol_name":"Cytosorbents Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDLbjrQrV:1","article_id":"2557595180","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557595180","pubTimestamp":1754596836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CytoSorbents Corporation  has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"CTSO":"Cytosorbents Corporation"},"translate_title":"细胞吸附剂2025年第二季度业绩：收入增长9%至960万美元；运营亏损稳定在360万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTSO":0.9},"content_text":"CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n    \n\n        CytoSorbents Corporation $(CTSO)$ has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}